Healthcare Active Stocks: Bristol-Myers Squibb (NYSE:BMY), MannKind (NASDAQ:MNKD), Achillion (NASDAQ:ACHN), Johnson & Johnson (NYSE:JNJ), Galena Biopharma (NASDAQ:GALE)

Bristol-Myers Squibb Co. (NYSE:BMY)‘s stock had its “hold” rating reiterated by research analysts at Edward Jones in a report released on Thursday. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was 0.44% in last session and finished the day at $48.00. Traded volume was 6.59million shares in the last session and the average volume of the stock remained 9.19million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.

MannKind Corporation (NASDAQ:MNKD) on May 12 reported financial results for the first quarter ended March 31, 2014. The net loss was $52.1 million, or $0.14 per share, compared with a net loss of $41.0 million, or $0.15 per share for the first quarter of 2013. MannKind Corporation (NASDAQ:MNKD) rose 3.67 percent to $10.73 Monday on volume of 8.89million shares. The intra-day range of the stock was $10.25 to $10.79. MannKind Corporation (NASDAQ:MNKD) has a market capitalization of $4.17billion.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on June 10 announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s stock on June 23, 2014 reported a decrease of -4.43% to the closing price of $7.77. Its fifty two weeks range is $2.26-$8.61. The total market capitalization recorded $752.10million. The overall volume in the last trading session was 9.28million shares. In its share capital, ACHN has 96.80million outstanding shares.

Johnson & Johnson (NYSE: JNJ) has joined forces with Vertex Pharmaceuticals Inc. (Nasdaq: VRTX-Free Report) for the worldwide development and commercialization of VX-787. The candidate is being developed for the treatment of influenza. Vertex Pharma will be receiving an upfront payment of $30 million from Johnson & Johnson as per the deal. Johnson & Johnson will enjoy full global development and commercialization rights to VX-787. On Monday, shares of Johnson & Johnson (NYSE:JNJ) dropped -0.49% to close the day at $104.75. Company return on investment (ROI) is 15.00% and its monthly performance is recorded as 3.75%. Johnson & Johnson (NYSE:JNJ) quarterly revenue growth is 10.80%.

Sales haven’t been frequent at RXi Pharmaceuticals Corp (NASDAQ:RXII). In fact, last insider sell was made by Large Shareholder Galena Biopharma, Inc (NASDAQ:GALE), selling 912,500 shares, at a price of $0.19 per share, during Q2 2013.Galena Biopharma Inc (NASDAQ:GALE) stock performance was 4.33% in last session and finished the day at $3.13. Traded volume was 5.18million shares in the last session and the average volume of the stock remained 3.99million shares. The beta of the stock remained 0.87. Galena Biopharma Inc (NASDAQ:GALE) insider ownership is 0.50%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone